Sign Out
Women of childbearing potential/Contraception in males and females: As the potential risk for humans is unknown, effective contraception must be used in women of child bearing potential.
Pregnancy: For pregnant women and women who may be pregnant, TARLIGE should be administered only if the expected therapeutic benefits outweigh the possible risks associated with treatment. An animal study (in rats) has shown that mirogabalin crossed the placenta (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Breast-feeding: The continuation or discontinuation of breastfeeding should be considered while taking account of the expected therapeutic benefits and the benefits of maternal feeding. An animal study (in rats) has shown that mirogabalin transferred to breast milk (see Pharmacology: Toxicology: Preclinical safety data under Actions).
Fertility: There are no clinical data on the effects of TARLIGE on female fertility. There was no adverse effect on fertility in an animal study (in rats) (see Pharmacology: Toxicology: Preclinical safety data under Actions).
